GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PetMed Express Inc (NAS:PETS) » Definitions » EBIT

PetMed Express (PetMed Express) EBIT : $-5.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is PetMed Express EBIT?

PetMed Express's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-3.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PetMed Express's annualized ROC % for the quarter that ended in Dec. 2023 was -11.81%. PetMed Express's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -42.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PetMed Express's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -15.25%.


PetMed Express EBIT Historical Data

The historical data trend for PetMed Express's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetMed Express EBIT Chart

PetMed Express Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.17 30.98 30.53 24.29 6.05

PetMed Express Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 -0.21 -2.13 -0.44 -3.07

Competitive Comparison of PetMed Express's EBIT

For the Pharmaceutical Retailers subindustry, PetMed Express's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetMed Express's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PetMed Express's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PetMed Express's EV-to-EBIT falls into.



PetMed Express EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PetMed Express  (NAS:PETS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PetMed Express's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-12.296 * ( 1 - 23.36% )/( (77.941 + 81.621)/ 2 )
=-9.4236544/79.781
=-11.81 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PetMed Express's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.296/( ( (28.794 + max(-7.749, 0)) + (28.437 + max(-25.539, 0)) )/ 2 )
=-12.296/( ( 28.794 + 28.437 )/ 2 )
=-12.296/28.6155
=-42.97 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.174 + 18.902 + 11.113) - (36.365 + 3.573 + 0)
=-7.749

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.93 + 34.577 + 9.602) - (68.58 + 3.068 + 1.4210854715202E-14)
=-25.539

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PetMed Express's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-5.855/38.392
=-15.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PetMed Express EBIT Related Terms

Thank you for viewing the detailed overview of PetMed Express's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PetMed Express (PetMed Express) Business Description

Traded in Other Exchanges
Address
420 South Congress Avenue, Suite 100, Delray Beach, FL, USA, 33445
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.
Executives
Gian Fulgoni director
Christine Chambers officer: CFO 1501 1ST AVENUE SOUTH, STE. 600, SEATTLE WA 98134
Mathew N Hulett director, officer: CEO & President 1621 NORTH KENT STREET, SUITE 1200, ARLINGTON VA 22209
Campbell Leslie C.g. director C/O COUPA SOFTWARE INC., 1855 S. GRANT STREET, SAN MATEO CA 94402
Diana G Purcel director C/O FAMOUS DVES OF AMERICA INC, 8091 WALLACE ROAD, EDEN PRAIRIE MN 55344
Moseley Mark Bradley Jr other: Chief Technology Info Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Daniel Job Pingree other: Chief Marketing Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Sandra Yvette Campos director 4900 E DUBLIN GRANVILLE RD, COLUMBUS OH 43081
Jacqueline Paula Smith other: Vice President of People 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Carolyn Carden other: VP of Product 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Peter Cobb director DSW, INC., 810 DSW DRIVE, COLUMBUS OH 43219
Jodi Watson director 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Frank J Formica director 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069
Bruce S Rosenbloom officer: Chief Financial Officer 6401 CONGRESS AVENUE, SUITE 250, BOCA RATON FL 33487
Menderes Akdag director, officer: Chief Executive Officer 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069